Loading...

Stericycle

Nasdaq:SRCL
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SRCL
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Commercial Services
Company description

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Stericycle has significant price volatility in the past 3 months.
SRCL Share Price and Events
7 Day Returns
-1.1%
NasdaqGS:SRCL
0.5%
US Commercial Services
-1.2%
US Market
1 Year Returns
-33.8%
NasdaqGS:SRCL
10.5%
US Commercial Services
3.4%
US Market
SRCL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stericycle (SRCL) -1.1% -2.4% -20.2% -33.8% -57.1% -61.4%
US Commercial Services 0.5% -0.1% 4.8% 10.5% 51% 80.6%
US Market -1.2% 0.7% 1.7% 3.4% 35.5% 41.6%
1 Year Return vs Industry and Market
  • SRCL underperformed the Commercial Services industry which returned 10.5% over the past year.
  • SRCL underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
SRCL
Industry
5yr Volatility vs Market

SRCL Value

 Is Stericycle undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stericycle to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stericycle.

NasdaqGS:SRCL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:SRCL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Commercial Services Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.672 (1 + (1- 21%) (77.11%))
1.054
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.054 * 5.96%)
9.01%

Discounted Cash Flow Calculation for NasdaqGS:SRCL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stericycle is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:SRCL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.01%)
2020 315.20 Analyst x5 289.13
2021 287.00 Analyst x1 241.50
2022 337.00 Analyst x1 260.12
2023 406.00 Analyst x1 287.47
2024 436.59 Est @ 7.53% 283.57
2025 463.19 Est @ 6.09% 275.97
2026 486.74 Est @ 5.08% 266.02
2027 508.05 Est @ 4.38% 254.70
2028 527.78 Est @ 3.88% 242.71
2029 546.45 Est @ 3.54% 230.52
Present value of next 10 years cash flows $2,631.71
NasdaqGS:SRCL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $546.45 × (1 + 2.73%) ÷ (9.01% – 2.73%)
$8,932.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,932.63 ÷ (1 + 9.01%)10
$3,768.25
NasdaqGS:SRCL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,631.71 + $3,768.25
$6,399.95
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,399.95 / 91.04
$70.3
NasdaqGS:SRCL Discount to Share Price
Calculation Result
Value per share (USD) From above. $70.30
Current discount Discount to share price of $45.61
= -1 x ($45.61 - $70.30) / $70.30
35.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Stericycle is available for.
Intrinsic value
35%
Share price is $45.61 vs Future cash flow value of $70.3
Current Discount Checks
For Stericycle to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Stericycle's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Stericycle's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stericycle's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stericycle's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SRCL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.53
NasdaqGS:SRCL Share Price ** NasdaqGS (2019-07-19) in USD $45.61
United States of America Commercial Services Industry PE Ratio Median Figure of 46 Publicly-Listed Commercial Services Companies 22.93x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stericycle.

NasdaqGS:SRCL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SRCL Share Price ÷ EPS (both in USD)

= 45.61 ÷ -3.53

-12.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stericycle is loss making, we can't compare its value to the US Commercial Services industry average.
  • Stericycle is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Stericycle's expected growth come at a high price?
Raw Data
NasdaqGS:SRCL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
94.3%per year
United States of America Commercial Services Industry PEG Ratio Median Figure of 34 Publicly-Listed Commercial Services Companies 1.64x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Stericycle, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Stericycle's assets?
Raw Data
NasdaqGS:SRCL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $28.27
NasdaqGS:SRCL Share Price * NasdaqGS (2019-07-19) in USD $45.61
United States of America Commercial Services Industry PB Ratio Median Figure of 86 Publicly-Listed Commercial Services Companies 1.83x
United States of America Market PB Ratio Median Figure of 5,247 Publicly-Listed Companies 1.79x
NasdaqGS:SRCL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SRCL Share Price ÷ Book Value per Share (both in USD)

= 45.61 ÷ 28.27

1.61x

* Primary Listing of Stericycle.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stericycle is good value based on assets compared to the US Commercial Services industry average.
X
Value checks
We assess Stericycle's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. Stericycle has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SRCL Future Performance

 How is Stericycle expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
94.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stericycle expected to grow at an attractive rate?
  • Stericycle's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Stericycle's earnings growth is expected to exceed the United States of America market average.
  • Stericycle's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SRCL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SRCL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 94.3%
NasdaqGS:SRCL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 3.3%
United States of America Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 15.4%
United States of America Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SRCL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SRCL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 3,901 2
2022-12-31 3,771 2
2021-12-31 3,639 3
2020-12-31 3,474 469 213 11
2019-12-31 3,397 405 92 11
NasdaqGS:SRCL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 3,421 92 -312
2018-12-31 3,486 166 -253
2018-09-30 3,521 207 148
2018-06-30 3,549 501 166
2018-03-31 3,583 451 -9
2017-12-31 3,581 509 23
2017-09-30 3,599 535 -47
2017-06-30 3,607 554 -21
2017-03-31 3,581 572 165
2016-12-31 3,562 561 178
2016-09-30 3,544 515 236
2016-06-30 3,373 457 244

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stericycle's earnings are expected to grow significantly at over 20% yearly.
  • Stericycle's revenue is expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SRCL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Stericycle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SRCL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 3.45 3.45 3.45 1.00
2020-12-31 2.23 2.96 1.68 7.00
2019-12-31 1.07 1.84 0.53 7.00
NasdaqGS:SRCL Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.53
2018-12-31 -2.91
2018-09-30 1.73
2018-06-30 1.95
2018-03-31 -0.11
2017-12-31 0.27
2017-09-30 -0.55
2017-06-30 -0.25
2017-03-31 1.94
2016-12-31 2.10
2016-09-30 2.78
2016-06-30 2.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Stericycle will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Stericycle's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stericycle has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SRCL Past Performance

  How has Stericycle performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stericycle's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stericycle does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Stericycle's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Stericycle's 1-year growth to the US Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
Stericycle's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stericycle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SRCL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 3,421.00 -312.10 792.00
2018-12-31 3,485.90 -253.30 804.90
2018-09-30 3,521.00 148.40 1,041.80
2018-06-30 3,548.90 166.40 1,000.60
2018-03-31 3,583.30 -9.00 877.70
2017-12-31 3,580.70 23.40 840.20
2017-09-30 3,599.25 -47.21 986.95
2017-06-30 3,606.60 -21.17 1,025.41
2017-03-31 3,580.52 164.92 965.33
2016-12-31 3,562.30 178.20 777.10
2016-09-30 3,544.25 236.23 715.11
2016-06-30 3,372.70 244.14 660.87
2016-03-31 3,196.77 294.68 604.69
2015-12-31 2,985.90 256.90 594.30
2015-09-30 2,774.55 268.75 506.29
2015-06-30 2,723.83 282.14 495.10
2015-03-31 2,648.97 276.25 481.99
2014-12-31 2,555.60 326.46 433.87
2014-09-30 2,446.55 322.09 427.91
2014-06-30 2,313.26 319.80 407.54
2014-03-31 2,198.96 315.90 384.03
2013-12-31 2,142.81 311.37 380.31
2013-09-30 2,078.55 303.28 358.86
2013-06-30 2,024.45 288.21 352.94
2013-03-31 1,966.88 277.76 342.43
2012-12-31 1,913.15 268.00 348.92
2012-09-30 1,856.07 262.22 321.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Stericycle has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Stericycle has efficiently used its assets last year compared to the US Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Stericycle improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Stericycle's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stericycle has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SRCL Health

 How is Stericycle's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stericycle's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stericycle is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stericycle's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Stericycle's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stericycle Company Filings, last reported 3 months ago.

NasdaqGS:SRCL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,570.50 2,811.70 48.20
2018-12-31 2,597.10 2,762.70 34.30
2018-09-30 2,932.60 2,838.00 52.00
2018-06-30 2,901.60 2,654.50 45.00
2018-03-31 2,952.10 2,720.70 49.40
2017-12-31 2,908.60 2,741.80 42.20
2017-09-30 2,818.72 2,778.50 52.17
2017-06-30 2,760.82 2,861.22 44.19
2017-03-31 2,892.48 2,863.34 47.02
2016-12-31 2,816.40 2,954.50 44.20
2016-09-30 2,858.79 3,012.78 40.35
2016-06-30 2,829.08 3,118.46 44.38
2016-03-31 2,818.49 3,152.15 45.72
2015-12-31 2,747.84 3,201.76 55.70
2015-09-30 2,734.44 1,516.09 669.17
2015-06-30 1,982.02 1,668.01 33.06
2015-03-31 1,950.01 1,575.39 38.40
2014-12-31 1,917.19 1,659.22 22.62
2014-09-30 1,880.19 1,677.41 42.46
2014-06-30 1,852.34 1,715.20 25.81
2014-03-31 1,785.55 1,370.38 43.41
2013-12-31 1,767.54 1,431.04 67.58
2013-09-30 1,722.73 1,403.17 64.03
2013-06-30 1,649.44 1,318.63 18.46
2013-03-31 1,625.47 1,272.70 13.20
2012-12-31 1,557.32 1,356.08 31.83
2012-09-30 1,492.86 1,297.15 16.67
  • Stericycle's level of debt (109.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (76.9% vs 109.4% today).
  • Debt is not well covered by operating cash flow (3.3%, less than 20% of total debt).
  • Stericycle is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Stericycle's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stericycle has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SRCL Dividends

 What is Stericycle's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stericycle dividends. Estimated to be 0% next year.
If you bought $2,000 of Stericycle shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stericycle's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stericycle's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SRCL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
United States of America Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 41 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:SRCL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stericycle has not reported any payouts.
  • Unable to verify if Stericycle's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stericycle's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stericycle has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Stericycle's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Stericycle's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stericycle afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stericycle has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SRCL Management

 What is the CEO of Stericycle's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cindy Miller
COMPENSATION $2,375,730
AGE 56
TENURE AS CEO 0.2 years
CEO Bio

Ms. Cindy J. Miller has been the President of Stericycle, Inc. since October 1, 2018, Chief Executive Officer since May 2, 2019 and as its Director since February 28, 2019. Ms. Miller served as Chief Operating Officer of Stericycle, Inc. from October 1, 2018 to May 2, 2019. Ms. Miller is responsible for the global operations of the Stericycle's medical waste, hazardous waste and secure information destruction lines, as well as the execution of Stericycle's Business Transformation. Ms. Miller joined Stericycle in October 2018 as part of an executive leadership development and succession planning process. Previously, Ms. Miller had a successful 30-year career at United Parcel Service (UPS) where she served in multiple roles of increasing leadership and international responsibility. She served as President of Global Freight Forwarding for United Parcel Service (UPS). She also served as President of UPS European Region and as Managing Director for several global and U.S. operating regions. Ms. Miller holds a B.A. in Humanities and Business from Pennsylvania State University and an Executive MBA from the London Business School.

CEO Compensation
  • Insufficient data for Cindy to compare compensation growth.
  • Cindy's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Stericycle management team in years:

0.5
Average Tenure
55
Average Age
  • The average tenure for the Stericycle management team is less than 2 years, this suggests a new team.
Management Team

Cindy Miller

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
0.2 yrs

Kurt Rogers

TITLE
Executive VP
COMPENSATION
$1M
AGE
47
TENURE
2 yrs

Dan Ginnetti

TITLE
Executive Vice President of International
COMPENSATION
$2M
AGE
50
TENURE
0.1 yrs

Janet Zelenka

TITLE
Executive VP & CFO
AGE
60
TENURE
0.1 yrs

Rich Hoffman

TITLE
Senior VP & Chief Accounting Officer
AGE
52
TENURE
2.2 yrs

David Stahl

TITLE
Executive VP & Chief Information Officer
AGE
54
TENURE
1.3 yrs

Jennifer Koenig

TITLE
Vice President of Corporate Communications & Investor Relations

Michael Weisman

TITLE
Executive VP and Chief Ethics & Compliance Officer
AGE
60
TENURE
1.3 yrs

S. White

TITLE
Executive Vice President of Communication & Related Services
TENURE
0.2 yrs

Joe Reuter

TITLE
Executive VP & Chief People Officer
AGE
57
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Stericycle board of directors in years:

1.2
Average Tenure
64
Average Age
  • The average tenure for the Stericycle board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Murley

TITLE
Chairman
COMPENSATION
$260K
AGE
69
TENURE
1.3 yrs

Cindy Miller

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
0.4 yrs

Mike Zafirovski

TITLE
Director
COMPENSATION
$185K
AGE
65
TENURE
6.7 yrs

Lynn Bleil

TITLE
Director
COMPENSATION
$191K
AGE
56
TENURE
4.2 yrs

Brian Anderson

TITLE
Director
COMPENSATION
$200K
AGE
68
TENURE
2.5 yrs

Thomas Chen

TITLE
Director
COMPENSATION
$185K
AGE
69
TENURE
5.2 yrs

Kay Priestly

TITLE
Director
COMPENSATION
$149K
AGE
63
TENURE
1.1 yrs

Ronee Hagen

TITLE
Director
COMPENSATION
$149K
AGE
73
TENURE
1.1 yrs

J. Hackney

TITLE
Director
AGE
49
TENURE
0.3 yrs

Steve Hooley

TITLE
Director
AGE
55
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Sep 18 Sell Brian Anderson Individual 30. May 17 13. Aug 18 -320 $81.76 $-22,457
X
Management checks
We assess Stericycle's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stericycle has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SRCL News

Simply Wall St News

What Kind Of Share Price Volatility Should You Expect For Stericycle, Inc. (NASDAQ:SRCL)?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … The fact that this is well above 1 indicates that its share price movements have shown sensitivity to overall market volatility. … What this means for you: Since Stericycle has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Is Stericycle, Inc.'s (NASDAQ:SRCL) Balance Sheet A Threat To Its Future?

Moreover, SRCL has generated cash from operations of US$92m in the last twelve months, resulting in an operating cash to total debt ratio of 2.9%, indicating that SRCL’s current level of operating cash is not high enough to cover debt. … With current liabilities at US$786m, the company has been able to meet these commitments with a current assets level of US$802m, leading to a 1.02x current account ratio. … Next Steps: SRCL’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Some Stericycle (NASDAQ:SRCL) Shareholders Have Copped A Big 57% Share Price Drop

By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. … Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround.

Simply Wall St -

Is Stericycle, Inc.'s (NASDAQ:SRCL) Balance Sheet A Threat To Its Future?

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Stericycle, Inc. … However, history shows that overlooked mid-cap companies have performed better on a risk-adjusted manner than the smaller and larger segment of the market. … SRCL’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns.

Simply Wall St -

What Does Stericycle, Inc.'s (NASDAQ:SRCL) Share Price Indicate?

(NASDAQ:SRCL), which is in the commercial services business, and is based in United States,. … As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … Let’s take a look at Stericycle’s outlook and value based on the most recent financial data to see if the opportunity still exists

Simply Wall St -

Why Stericycle, Inc.’s (NASDAQ:SRCL) Return On Capital Employed Looks Uninspiring

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Understanding Return On Capital Employed (ROCE). … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Does Stericycle, Inc.'s (NASDAQ:SRCL) Debt Level Pose A Problem?

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Stericycle, Inc. … While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. … This article will examine SRCL’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth.

Simply Wall St -

Is Stericycle, Inc.'s (NASDAQ:SRCL) CEO Pay Justified?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Charles Alutto's Compensation Compare With Similar Sized Companies. … has a market cap of US$3.4b, and is paying total annual CEO compensation of US$3.8m.

Simply Wall St -

Is Stericycle, Inc.'s (NASDAQ:SRCL) ROE Of 5.6% Concerning?

This article is for those who would like to learn about Return On Equity (ROE). … Our data shows Stericycle has a return on equity of 5.6% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Should You Know About Stericycle Inc's (NASDAQ:SRCL) Capital Returns?

This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … This is because the actual cash flow generated by the business dictates the potential for income (dividends) and capital appreciation (price increases), which are the two ways to achieve positive returns when buying a stock. … Therefore, looking at how efficiently Stericycle is able to use capital to create earnings will help us understand your potential return.

Simply Wall St -

SRCL Company Info

Description

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. It operates through three segments: Domestic and Canada Regulated Waste and Compliance; International Regulated Waste and Compliance; and Domestic Communication and Related Services. It collects and processes regulated and specialized waste for disposal services; and collects personal and confidential information for secure destruction, recall/return, and communication services. The company’s services also include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, and compliance services; and regulated recall and returns management communication, logistics, and data management services for expired, withdrawn, or recalled products. In addition, it offers compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names; and live voice and automated communication services, including afterhours answering, appointment scheduling, appointment reminders, secure messaging, and event registration. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, long-term care facilities, etc.; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Lake Forest, Illinois.

Details
Name: Stericycle, Inc.
SRCL
Exchange: NasdaqGS
Founded: 1989
$4,152,376,133
91,040,915
Website: http://www.stericycle.com
Address: Stericycle, Inc.
28161 North Keith Drive,
Lake Forest,
Illinois, 60045,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SRCL Common Stock Nasdaq Global Select US USD 23. Aug 1996
DB SY9 Common Stock Deutsche Boerse AG DE EUR 23. Aug 1996
LSE 0L9O Common Stock London Stock Exchange GB USD 23. Aug 1996
Number of employees
Current staff
Staff numbers
22,500
Stericycle employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 01:48
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/18
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.